Correspondence
In Brief Fibroblastic reticular cells control matrix production for lymph node conduit function. Martinez et al. show that matrix production is reduced and conduit flow is altered during lymph node expansion. Matrix deposition by fibroblastic reticular cells is controlled by CLEC-2/podoplanin signaling and directed unilaterally into conduit structures by LL5-b-tethered microtubules. (Link et al., 2007) . Once thought to provide only the necessary scaffolds to support the architecture of the tissue, LN stromal cells are now recognized as key players in immunity (Buechler and Turley, 2018) . Four main populations of stromal cells can be defined in LNs: podoplanin (PDPN) À CD31 + blood endothelial cells (BECs), PDPN + CD31 + lymphatic endothelial cells (LECs), PDPN + CD31 À fibroblastic reticular cells (FRCs), and PDPN À CD31 À double-negative cells (DNs) (Novkovic et al., 2018) . Among these, the FRC population is the most abundant subset. A recent small conditional RNA sequencing (scRNA-seq) analysis showed that FRCs may contain different subpopulations with specific locations and functions (Rodda et al., 2018) . FRCs form a connected 3-dimensional (3D) network that spans the T cell area and interfollicular regions of LNs. FRCs regulate the lymphocyte homeostasis (Cremasco et al., 2014; Link et al., 2007) and induction of peripheral tolerance (Dubrot et al., 2014; Fletcher et al., 2010; Lee et al., 2007) . Furthermore, contraction through the FRC network also regulates LN size during immune responses. Interactions between FRC and C-type lectin-like receptor 2-expressing (CLEC-2 + ) migratory dendritic cells (DCs) transiently inhibit PDPN-dependent actomyosin contractility during the acute phase of the immune response (Acton et al., 2014; Astarita et al., 2015) , allowing rapid LN expansion.
LNs also function as filters for lymph-born antigens (Radtke et al., 2015; Randolph et al., 2017) . Soluble antigens reach the LN first in a wave of draining-type diffusion ahead of a secondary wave of migratory antigen-presenting cells. Collected by lymphatic capillaries in the peripheral tissue, the lymph converges in afferent lymphatic vessels that merge with the LN capsule and flows within the subcapsular sinus (SCS). The lymph percolates through trabecular and cortical sinuses that flow into the LN medulla before leaving via efferent lymphatic vessels. A sample of low-molecular-weight molecules (<70 kDa) (Gretz et al., 2000; Nolte et al., 2003; Roozendaal et al., 2009; Sixt et al., 2005) is permitted to flow directly through the LN parenchyma within an intricate tubular system called the conduit network (Roozendaal et al., 2009) . The conduit network is composed of bundled and aligned extracellular matrix (ECM) components enwrapped by FRCs, the main producers of ECM in the LN Sixt et al., 2005; Sobocinski et al., 2010) . No other fibrillar ECM structures are found in the LN parenchyma. While we are starting to understand how the FRC network reacts during LN expansion, it is not yet known how the non-cellular ECM components are remodeled and how rapid expansion of the LN may affect the function of the conduit. In other contexts, inflammation goes hand in hand with tissue remodeling. Injury-induced loss of the ECM is rapidly replenished by biogenesis and crosslinking (Xue and Jackson, 2015) . Chronic inflammation, as it occurs in cancers or some viral infections, induces deregulation of this process, leading to fibrosis (Wynn and Ramalingam, 2012) . LN fibrosis can occur in tumor-draining LNs or in some cases of chronic viral infection (Riedel et al., 2016; Rohner et al., 2015; Schacker et al., 2006; Zeng et al., 2011) ; however, more commonly, LNs undergo a virtually unlimited number of inflammatory episodes throughout an individual's lifetime and LN fibrosis does not occur. Therefore, we hypothesized that a specific mechanism must be in place to both confine ECM secretion exclusively to the conduit and to avoid the accumulation of aberrant ECM during inflammation.
In this study, we focus on ECM remodeling by FRCs during LN expansion and the interconnection between the cellular and ECM components of the conduit network. We demonstrate depletion and disruption of ECM components of the conduit during acute LN expansion. We show that CLEC-2 binding to PDPN + FRCs modulates ECM production at both mRNA and protein levels. Furthermore, the CLEC-2/PDPN axis regulates polarized microtubule organization in FRCs to direct and contain ECM deposition.
RESULTS

Extracellular Matrix Components of the Conduit Are Reduced during Acute LN Expansion
To ask how ECM structures were maintained and remodeled during acute LN expansion, a period of rapid tissue growth, we first examined LN ECM structures in the steady state. Using the passive clarity technique (PACT) (Yang et al., 2014) , we imaged collagen IV in intact naive inguinal LNs ( Figure 1A ; Video S1). This abundant basement membrane protein surrounded the LN vasculature and formed an intricate 3D connected network spanning the whole LN parenchyma Sixt et al., 2005; Sobocinski et al., 2010) , corresponding to the conduit network. Electron microscopy revealed the detail of condensed fibrillar bundles consisting of >200 collated fibers of ECM enwrapped by FRCs ( Figure 1B ). Co-staining of the basement membrane protein laminin and the FRC marker PDPN confirmed that in LN parenchyma, ECM structures are found exclusively associated with the FRC network forming the conduit (Bajé noff and Germain, 2009) and vasculature ( Figure 1C ).
We immunized mice with ovalbumin emulsified with incomplete Freund's adjuvant (IFA/OVA) and compared the density of collagen IV structures in LNs after 4 and 14 days ( Figure 1D ). We observed that the FRC network appeared stretched but connected at day 4 and that collagen IV structures were less prominent. Using podoplanin staining as a mask, we quantified collagen IV intensity exclusively within the FRC cellular network and found a progressive loss and disruption of conduit matrix over time in inflamed LNs ( Figure 1E ). We obtained similar results for collagen I and collagen VI (Figures 1F and 1G) , indicating that while the FRC cellular network remained connected and intact, the accompanying ECM components of the conduit remained associated with the FRCs but were no longer replete.
CLEC-2 Binding Regulates ECM Production by FRCs
FRCs rapidly change their morphology and network architecture in response to CLEC-2 + migratory DCs (Acton et al., 2014) . We hypothesized that the remodeling of the cellular network may also affect the remodeling of the associated ECM downstream of the same DC/stromal contacts. We stimulated FRCs in vitro with CLEC-2-Fc recombinant protein and compared transcriptional profiles by RNA-seq (Figures 2 and S1). Bulk analysis of the transcriptomic data comparing 6-and 24-h CLEC-2-Fc treatment revealed that CLEC-2-Fc induced a transient and largely reversible gene regulation response in FRCs ( Figure S1A ). This transient transcriptional regulation follows kinetics similar to how CLEC-2 inhibits PDPN-dependent contractility in FRCs (Acton et al., 2014) . Gene Ontology analysis (Mi et al., 2013 showed that genes encoding proteins in the extracellular space/ region were most enriched among CLEC-2-Fc-regulated genes (Figure 2A ). Using the Matrisome database (Naba et al., 2012 (Naba et al., , 2016 (Naba et al., , 2017 of all ECM proteins and associated factors, we found that FRCs expressed 570 of 743 matrisome genes in vitro, of which 75 (13%, across all matrisome categories) were regulated >2-fold 6 h after CLEC-2-Fc binding (Figures 2B and S1B) .
FRCs regulated 35 core matrisome genes (>2-fold) in response to CLEC-2-Fc, including 1 collagen (Col8a2), 23 glycoproteins, and 6 proteoglycans ( Figure 2C ). The downregulated glycoproteins were mostly associated with cell-matrix adhesion and migration, including Nov, Sparcl1, Ntn1, Igfbp5, Ndnf, Spon2, Efemp1, and Fbln7 (de Vega et al., 2016; Ellis et al., 2003; Gagliardi et al., 2017; Jia et al., 2005; Ohashi et al., 2014; Song et al., 2011; Sureshbabu et al., 2012; Yin et al., 2018) . The glycoprotein genes induced had more pleiotropic roles, such as growth factor signaling (Ctgf, Tsku, Wisp1, and Ltbp2) (Enomoto et al., 2018; Lee et al., 2010; Niimori et al., 2014; Ono et al., 2018) or immunomodulation (Spp1, Tnc, and Crispld2) (Castello et al., 2017; Murdamoothoo et al., 2018; Wang et al., 2009) . The regulation of proteoglycan expression by CLEC-2-Fc was more evident at 24 h, suggesting that CLEC-2-Fc may be indirectly regulated (e.g., CTGF/CCN2 represses Ogn, Dcn, and Omd; Seher et al., 2011) . CLEC-2-Fc increased the expression of Prg4, which inhibits synoviocyte cell/matrix adhesion (Qadri et al., 2018) .
Most of the 17 ECM-affiliated genes that were regulated by CLEC-2-Fc were linked to cytoskeleton regulation (Afratis et al., 2017; Casazza et al., 2007; Hamm et al., 2016) (Figure 2C ), including members of the semaphorin-plexin system, which provides guidance cues for migration (Casazza et al., 2007) . Known to inhibit axonal growth (Casazza et al., 2007) , the expression of Sema6c, Sema5a, Sema3f, Sema3e, Sema3a, and Sema3d were reduced upon CLEC-2-Fc treatment, hinting that FRCs may spread using similar mechanisms. Of note, CLEC-2-Fc induced the expression of Sema7a, which represses ECM production in other fibroblasts (Esnault et al., 2017) .
CLEC-2-Fc regulation of 23 ECM regulators ( Figure 2C ) mainly affected protease inhibitors, including the upregulation of Serpine1, Timp1, and Timp3, key in the negative regulation of matrix metalloproteinase (MMP) activity (Flevaris and Vaughan, 2017; Zhai et al., 2018) . Also upregulated are Sulf1 and Tll1, which are involved in ECM biogenesis (Kessler et al., 1996; Nagamine et al., 2012) . CLEC-2-Fc repressed the expression of several ECM regulator genes with prominent roles in ECM degradation: Hyal1 (hyaluronidase-1) (Harada and Takahashi, 2007) (Porter et al., 2005) , Adamts5 (Evanko et al., 2012) , Adamts7 (Riessen et al., 2001) , Adamts9 (Yoshina et al., 2012) , Adamts15 (Dancevic et al., 2013) , Adam9 (Roychaudhuri et al., 2014) , and Mmp16 (Roth et al., 2017) . Anxa8
Htra3 Adam9 These data indicate that FRCs can substantially alter their transcriptional profile following CLEC-2 binding and that transcriptional regulation may play an important role in ECM remodeling and cell matrix adhesion in FRCs. Furthermore, the induction of protease inhibitors plus the repression of proteases suggest that the observed loss of ECM within the conduit during LN expansion ( Figure 1D ) is unlikely to be due to degradation by FRCs. Furthermore, since we observed that collagens (I, IV, and VI) are reduced in vivo in inflamed LNs ( Figure 1D ) but were not transcriptionally regulated by CLEC-2, this transcriptional regulation alone cannot fully explain the reduced ECM observed ( Figure 1D ).
To investigate whether the CLEC-2/ PDPN signaling axis regulates ECM production at the protein level, we undertook a proteomic analysis of FRC-derived matrices in vitro ( Figure S2 ). We generated CLEC-2-Fc-secreting FRCs to allow constant CLEC-2 stimulation and compared them to PDPN-depleted FRCs (PDPN knockdown [KD]) (Acton et al., 2014) and a control FRC cell line. Mass spectrometry analysis detected a similar number of proteins in all 3 FRC cell lines, in which 96 proteins were matrisomal proteins, with almost 90% overlap among the samples ( Figure S2A ). PDPN depletion phenocopies the loss of contractility induced by CLEC-2 binding (Acton et al., 2014) ; in contrast, when comparing ECM protein production, PDPN KD FRCs appeared qualitatively different from either control or CLEC-2-Fc-secreting FRCs ( Figure S2B ). PDPN KD FRC-derived matrices showed an overall reduction in ECM components, whereas CLEC-2-Fc-secreting FRCs and controls were more closely aligned ( Figure S2C ). This suggests that the loss of PDPN expression is not equivalent to CLEC-2 modulation of PDPN function in the case of matrix production.
While the CLEC-2/PDPN signaling axis influenced both matrix transcription (Figures 2A-2C ) and protein production ( Figure S2 ), how these changes translated to fibril formation, relevant to conduit remodeling in vivo, was still unclear. Staining of decellularized FRC-derived matrices for fibronectin and collagen VI showed that ECM structures formed by CLEC-2-Fc-secreting FRCs appeared disorganized compared to controls, with lower alignment, large empty spaces, and lower median intensity of matrix fibers ( Figures 2D and 2E ). In this functional assay, PDPN KD FRCs phenocopied the effect of CLEC-2-Fc in matrix deposition and organization. These experiments demonstrate that CLEC-2/PDPN signaling regulates ECM remodeling at multiple levels, gene expression, protein production, and secretion and fibril arrangement. These results also indicate that PDPN expression by FRCs is a key requirement for FRCs to produce, deposit, and align ECM components, and that this process is modulated by CLEC-2.
Signaling Cascades Regulated by CLEC-2 in FRCs
The above results suggest that additional cellular mechanisms are likely to regulate ECM deposition in FRCs. To address the CLEC-2/PDPN-dependent signaling cascades controlling ECM organization, we performed an unbiased phosphoproteomics analysis of FRCs by tandem mass tag mass spectrometry (TMT-MS) (Tape et al., 2016) ( Figure 3A ). Control FRCs were stimulated with CLEC-2-Fc for 15 min or 24 h to capture immediate and late signaling responses. As expected, the total protein levels did not differ significantly following treatment ( Figure 3B ). However, phosphoproteome analysis revealed that CLEC-2-Fc induced a rapid and transient signaling response in FRCs (Figure 3C) . At 15 min, z400 phosphorylation sites were regulated by CLEC-2-Fc ( Figure 3D ), corresponding to 77 proteins. In contrast, after 24 h, only 8 phosphorylation sites corresponding to 6 proteins were regulated compared to controls, confirming the transient and reversible nature of responses to CLEC-2/ PDPN engagement ( Figure 3D ).
To elucidate signaling cascades regulated by CLEC-2, we performed kinase target analysis (15 min dataset). We found that CSNK2B and CDK1 regulated the highest number of predicted targets ( Figure 3E ). Gene Ontology analysis of hits (Mi et al., 2013 highlighted intracellular protein transport pathways ( Figure 3F ) that were relevant to the transport and deposition of cargo such as ECM components. However, using a GFPbased assay, we found no reduction in protein secretion in either CLEC-2-Fc-treated or PDPN KD FRCs ( Figure S3 ). Nevertheless, the impaired ECM deposition that was observed in both CLEC-2-Fc-treated and PDPN KD FRCs ( Figure 2D ) prompted a closer look at the phosphoproteomic data. Secretion of large cargo proteins such as ECM components requires vesicle transport via such cytoskeletal structures as the microtubule network (Noordstra and Akhmanova, 2017) . We found that several key regulators of microtubule function were post-translationally modified by CLEC-2-Fc stimulation, including cytoplasmic linker protein 170 (CLIP-170), cytoplasmic dynein heavy chain 1, and pleckstrin homology-like domain family B member 2 (LL5b). While the direct function of these regulatory sites has not been previously described, these data presented strong evidence that CLEC-2 altered the organization of microtubules in FRCs, a possible regulatory mechanism of ECM deposition in LNs.
CLEC-2 Binding Controls Microtubule Organization in FRCs via LL5b
LL5b forms complexes that attach plus ends of microtubules to the cell membrane, providing a secretory pathway for localized exocytosis, which facilitates apicobasal cell polarity in epithelial cells (Hotta et al., 2010; Lansbergen et al., 2006; Noordstra and Akhmanova, 2017; Stehbens et al., 2014) . Given that ECM components in LNs are tightly compartmentalized by FRCs within the conduit, we reasoned that FRCs may be using a similar pathway to secrete ECM. We therefore examined the role of LL5b in ECM deposition by FRCs. We found that both CLEC-2-Fc treatment and PDPN KD reduced LL5b protein and mRNA levels in FRCs ( Figures 4A and 4B ). We attempted unsuccessfully to overexpress a phosphomimetic mutant (LL5b S465E) in FRCs, leading us to hypothesize that phosphorylation of LL5b at S465 may target LL5b for degradation.
Control FRCs clustered LL5b at the cell periphery ( Figure 4C ); however, this accumulation was absent in PDPN KD FRCs and more cytoplasmic in CLEC-2-Fc-treated cells (Figures 4C and 4D) . The reduced peripheral localization of LL5b coincided with the lower density of microtubules at the cell periphery in PDPN KD and CLEC-2-Fc-treated cells ( Figure 4E ). We confirmed the colocalization of LL5b with cortical microtubules in control FRCs, in which LL5b + areas presented a higher microtubule density compared to areas lacking LL5b ( Figure 4F ). To investigate whether LL5b was required for microtubule attachment to the cortex in FRCs, we silenced LL5b expression using small interfering RNA (siRNA) ( Figure 4G ), which resulted in a corresponding loss of microtubules from the periphery ( Figure 4H ). LL5b-silenced FRCs also showed significantly reduced matrix deposition ( Figures 4I and 4J ), phenocopying the disrupted matrix generated following either CLEC-2-Fc treatment or PDPN depletion ( Figure 2H ) and confirming that LL5b is necessary for ECM deposition in FRCs.
Loss of FRC Adhesion and Reorganization of Microtubule Networks
LL5b is recruited to mature focal adhesion complexes, which require Rho-kinase (ROCK)/myosin-mediated contractility (Katoh et al., 2001; Stehbens et al., 2014) . Since the CLEC-2/ PDPN signaling axis inhibits actomyosin contractility in FRCs (Acton et al., 2014) , we predicted it may also alter FRC adhesion to the underlying conduit and therefore inhibit the localization of LL5b and microtubules to the cell cortex. We compared the structure and localization of focal adhesions (p-paxillin) and LL5b between FRC cell lines. In controls, LL5b clustered directly adjacent to elongated mature focal adhesions (Stehbens et al., 2014) (Figures 5A and 5B ). However, CLEC-2-Fc-treated and PDPN KD cells presented significantly shorter focal adhesions ( Figures 5A and 5B ). This was phenocopied by the direct inhibition of ROCK (Y-27632) ( Figures 5A and 5B ). This result shows that when focal adhesion maturation is disrupted, there is a concordant loss of LL5b clustering, linking actomyosin contractility, cell matrix adhesion, and LL5b recruitment in an integrated mechanism ( Figures 5A and 5B) . To test these linked outcomes in a more physiological assay, we stimulated FRCs with either control or CD11c DCLEC-2 bone marrow-derived dendritic cells (BMDCs). Cultured alone, FRCs displayed prominent F-actin stress fibers and mature elongated focal adhesions to which microtubule bundles docked in abundance ( Figures 5C and  5D ). Interaction with control (CLEC-2 + ) BMDCs induced the loss of actin stress fibers, shorter focal adhesions, and lower microtubule density at the periphery (Figures 5C and 5D ). This change in FRC morphology and function was not observed with CD11c DCLEC-2 BMDCs (Figures 5C and 5D ), demonstrating that DC-induced inhibition of actomyosin contractility and microtubule localization requires CLEC-2.
We next asked whether LL5b directs the microtubule-mediated deposition of matrix components in the FRC network in vivo. High-resolution imaging of LN tissue revealed that in naive LNs, the entire FRC network expressed high levels of LL5b, and its localization was always polarized inward toward the ensheathed conduit ( Figure 5E ). In contrast, in inflamed LNs, we observed many regions of the FRC network that lacked polarized localization of LL5b, coinciding with the loss of laminin in the same region ( Figure 5E ). This is a direct translation of the in vitro studies that predicted the loss of LL5b when matrix adhesion is lost (Figures 4  and 5) . These data require us to consider FRCs as polarized cells, exhibiting apical and basolateral cell polarity similar to epithelial sheets (Noordstra and Akhmanova, 2017) , but enwrapping the conduit similar to Schwann cells enwrapping nerve fibers (Tricaud, 2018) . The inner surface of the FRC adheres to the conduit and recruits LL5b for ECM secretion, while the outer surface of the FRC excludes ECM, allowing optimal interaction with lymphocytes and antigen-presenting cells. Polarized and localized exocytosis in FRCs, directed by LL5b, can mechanistically explain how ECM components are exclusively found within the conduit and not elsewhere in the LN parenchyma.
Conduit Size Exclusion and Flow Persist during LN Expansion
We next asked how remodeling the ECM would affect conduit function. We compared the flow of fluorescently labeled dextrans through the LN sinuses and conduits of naive and acutely inflamed LNs (5 days post-immunization). It has been previously shown that 10-kDa dextrans can flow through the conduit, while those >70 kDa are too large and are retained in the subcapsular sinus (Gretz et al., 2000; Nolte et al., 2003; Roozendaal et al., 2009; Sixt et al., 2005) . In accordance with previous studies, the 500 kDa dextran was excluded from all but the most proximal branches of the conduit in both naive and inflamed LNs (Figure S4A) , meaning that the filtering function and size exclusion of the conduit network are maintained during LN expansion (Figure S4A ). Furthermore, these results indicated that ECM loss within the network did not impede the overall flow of small soluble molecules through LNs. However, looking in more detail, we noticed the presence of numerous gaps or interruptions in dextran flow (10 kDa) through inflamed LNs, in which only <20% of the FRCs network was dextran + in inflamed LNs (Figure 6A, right panel) . We found that the presence of dextran flow in inflamed LNs perfectly correlated with FRCs that had maintained both polarized LL5b and laminin ( Figure 6B ), indicating that conduit function is dysfunctional in many sections of the FRC network. However, despite the substantial reduction in conduit structures during acute expansion, the overall global distribution of small molecules through the conduit is maintained, reinforcing the robustness of the FRC network (Novkovic et al., 2016) . We asked whether the interruptions in conduit flow observed in inflamed LNs would affect antigen uptake. Using flow cytometry, we found a similar percentage of dextran + cells in inflamed LNs compared to naive ( Figure 6C ) within 90 min post-dextran injection. The total number of dextran + cells was approximately doubled, but this is in line with the increase in LN cellularity (Figure 6Di) . We found increased numbers of dextran + cells within both MHC-II À and MHC-II + populations (Figure 6Dii) , with MHC-II + cells representing 80% of all dextran + cells (Figure S5B) , the majority of these being CD11c À/low CD11b + (monocytes/macrophages) cells in inflamed LNs (Figure 6Diii ). Upon examination of the tissue sections, we found that the increased numbers of dextran + monocytes/macrophages in inflamed LNs may result from the active recruitment of more CD11b + monocytes/macrophages to conduits ( Figure 6E ). We observed double the number of CD11b + cells interacting with the FRC network per area compared to naive controls (Figures 6E and 6F) . Overall, we find that despite the local loss of conduit function (Figure 6A) , the global robustness of the conduit network together with the increased monocytes/macrophage recruitment to conduits is able to maintain soluble antigen uptake throughout LN expansion.
Conduit Sampling by CD11b + Cells Is Increased in
DISCUSSION
Our results show that conduit flow within the T cell area conduit network is locally compromised during adaptive immune responses and that ECM components are lost or effectively diluted during early LN expansion. As a result, we observe discontinuous conduit flow within inflamed LNs, indicating areas of potential leakage. However, if conduits were leaking soluble antigens, then we may expect increased indiscriminate uptake by the many phagocytic cells within the tissue. Instead, we see that dextrans continue to be sampled from the conduits by a subset of myeloid cells and that an increased number of CD11b + monocytes/macrophages are recruited to interact with the FRC network. We conclude that the conduit network is sufficiently robust in offering alternative routes around the dysfunctional sections. Conduit size exclusion requires plasmalemma vesicle-associated protein (PLVAP) expression by the lymphatic endothelial cells lining the sinus (Rantakari et al., 2015) . Our study provides further evidence that this barrier remains intact during early LN expansion, continuing to protect lymphoid tissue from intact pathogens.
Previous work has described the complex architecture of the conduit network in the steady state, and it is known that FRCs produce and organize ECM components Roozendaal et al., 2009; Sixt et al., 2005; Sobocinski et al., 2010) . We show that FRCs exhibit a type of apical/basolateral cell polarity and organize microtubule networks to direct ECM deposition unilaterally into conduit structures. Recruitment of LL5b facilitates the docking and attachment of the plus ends of microtubules to the cell membrane at sites of FRC-matrix adhesion and enables matrix deposition.
We found that CLEC-2 binding to FRCs regulates their matrix remodeling at both transcriptional and protein levels and also regulates FRC adhesion, contractility, and microtuble networks via LL5b recruitment, transiently inhibiting matrix deposition. This mechanism would explain how LNs are able to avoid the aberrant accumulation of excess ECM while enduring repeated episodes of inflammation. We have previously shown that CLEC-2 + DCs inhibit PDPN-dependent contractility in FRCs (Acton et al., 2014) . This weakens FRC adhesion and in turn inhibits the recruitment of LL5b to the conduit. LL5b expression is essential for FRCs to organize microtubules and form ECM matrices, and it is exclusively localized basolaterally in FRCs in association with laminin in vivo. We find that LL5b basolateral localization is disrupted during LN expansion, which can account for the progressive loss of ECM during LN expansion.
Our results confirm that the FRC cellular network remains connected in inflamed LNs (Acton et al., 2014; Astarita et al., 2015) , even though the conduit flow is locally disrupted. This also indicates that FRC-FRC connectivity is prioritized over maintaining ECM production. Our data suggest that to expand the LN rapidly, FRCs detach temporarily from the conduit and halt matrix production, leading to the local loss of conduit function as pre-existing ECM fibers are stretched through the expanding tissue. However, the remaining intact sections of conduit are sufficient to channel the lymph throughout the LN parenchyma. Recent observations based on FRC ablation and a graph theory-based systems biology approach have demonstrated that FRCs establish ''small-world'' networks (Novkovic et al., 2016; Textor et al., 2016) . High local connectivity ensures the high topological robustness of the FRC network, which can tolerate the loss of 50% of all FRCs (Novkovic et al., 2016) . We propose that a similar principle applies to conduit flow, in which interruption of the conduit network is efficiently overcome by sufficient alternative routes. These findings lead us to the question of how conduit flow is determined, whether as a result of pressure from tissues and afferent lymphatics pushing fluid through the conduit network or, alternatively, whether the draw of fluid leaving the system via high endothelial venules (HEVs) and efferent vessels provides a pulling force. Since we find no evidence for leakiness of conduits, which may be predicted in a model of pushing forces, our data may suggest that flow is determined by pull from the circulation. We cannot exclude that the dysfunctional conduit flow that we observe in many sections of the FRC network ( Figure 6) is not due to a disruption or an alteration in the drainage of tissue fluid such that conduits do not fill properly.
In contexts outside the LN, PDPN is often upregulated by fibroblasts in inflammatory settings (Hisakane et al., 2016; Kim et al., 2015; Shindo et al., 2013) . In these scenarios, the ECM deposition by these fibroblasts could also be regulated and modified by contact with CLEC-2 + myeloid cells or platelets leaking from inflamed vessels. It will be interesting to understand whether the same CLEC-2-dependent transcriptional and protein expression regulation occurs in other PDPN + fibroblasts. Since the CLEC-2/PDPN signaling axis also regulates FRC actomyosin contractility, this signaling pathway may also control how ECM is aligned and organized in other tissues.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS Mice
Experiments were performed in accordance with national and institutional guidelines for animal care and approved by the Institutional Animal Ethics Committee Review Board, Cancer Research UK and the UK Home Office. Wild-type C57BL/6J mice were purchased from Charles River Laboratories. PDGFRaKI-H2BGFP mice (B6.129S4-Pdgfratm11(EGFP)Sor/J) were purchased from Jackson Laboratories. Generation of CD11c DCLEC-2 was achieved as previously described (Acton et al., 2014) by crossing Clec1b fl/fl with CD11c-Cre mice (B6.Cg-Tg(Itgax-cre)1.1Reiz). Both males and females were used for in vivo and in vitro experiments and were aged 8-12 weeks. Cre-negative littermates were used as controls in all experiments.
Animal procedures Immunisations
Mice were immunized via subcutaneous injection in the right flank of 100 mL of an emulsion of OVA in CFA or IFA (100 mg OVA per mouse) (Hooke Laboratories). After 5 days, mice were culled and inguinal LNs from both flanks (naive and inflamed) were extracted for paired histological studies or flow cytometry analysis. Dextran uptake in vivo Five days after immunization, mice were injected subcutaneously in both flanks with 20 mL of dextran solution (100 mg dextran per flank) conjugated to: Cascade Blue (10kDa dextran), Tetramethylrhodamine (70 kDa dextran) or Fluorescein (500 kDa dextran), all from Thermo Fisher Scientific. Mice were culled and paired inguinal LNs (inflamed versus non-inflamed) collected after 30 or 90 minutes for histological and flow cytometry analysis respectively.
Cell lines
In vitro experiments were performed using immortalized WT (control) and PDPN knockdown mouse FRC cell lines previously described (Acton et al., 2014) . For CLEC-2-Fc expression by FRCs, Clec1b cDNA was cloned into pFUSE-rIgG-Fc2 plasmids (Invivogen) and transfected into WT FRCs using lipofectamine 2000 (Thermo Fisher Scientific). Transfected cells were selected by prolonged culture with zeocin 100 mg/ml (Invivogen) and secretion of CLEC-2-Fc was confirmed by western blotting for cell-derived supernatants (data not shown). FRC cell lines were cultured in DMEM plus glutamax (Life Technologies, Invitrogen) supplemented with 10% FBS, Penicillin-Streptomycin (100 U/mL) and 1% Insulin-Transferrin-Selenium (Life Technologies, Invitrogen) at 37 C in 10% CO 2 . Cells were passaged when they reached 80%-90% confluence, by incubating in Cell Dissociation Buffer (Thermo Fisher Scientific) for 10 minutes at 37 C, plus a gentle treatment of 1 min with Trypsin 0.25% (Thermo Fisher Scientific). When indicated, FRCs were treated with 50 mg/ml CLEC-2-Fc or 10 mM ROCK inhibitor Y-27632 dihydrochloride (Tocris) for the last 2 hr of culture.
Primary cultures
Bone marrow cells were obtained from tibias and femurs from CD11c DCLEC-2 mice and Cre-negative control littermates. Whole bone marrow was cultured in non-treated 10 cm Petri dishes in RPMI media supplemented with 10% FBS and Penicillin-Streptomycin (100 U/mL) plus 20 ng/ml of recombinant murine GM-CSF (Peprotech) at 4x10 6 cells / 13 mL of medium. After 3 days, cultures were supplemented with 4 mL of fresh media plus 37.2 ng/ml GM-CSF. After 6 days in culture, BMDCs were stimulated with 10 ng/ml Lipopolysaccharides from Escherichia coli 0111:B4 (Sigma-Aldrich) for 24 hr before harvesting.
METHOD DETAILS
Tissue clearing and immunostaining of intact LNs
We used a modified version of the PACT (passive clarity technique) for whole LN staining based on previous publication (Yang et al., 2014) . In brief, AntigenFix (DiaPath) fixed LNs were incubated overnight at 4 C in 40% acrylamide + 25 mg/ml 2,2 0 -Azobis(2-methylpropionamidine) dihydrochloride (Sigma). Infused samples were degassed with nitrogen for 5 min and then incubated for 6 hr at 37 C. Samples were washed in PBS for 24 hr and incubated for 4 days with 8% SDS PBS solution at 37 C. After washing with PBS for 24 hr, LNs were incubated with 1:100 anti-collagen IV in PBS 2% goat serum (Abcam) 0.1% Triton X-100 (Sigma-Aldrich) 0.01% sodium azide (Webscientific) for 4 days at 37 C (rotation). Same concentration of the antibody was added after 1 and 2 days. Then wash in PBS at 37 C (rotation) for 24 hr and incubated with the secondary antibody in same conditions as the primary. Samples were transferred to a 2 g/ml Histodenz (Sigma-Aldricht), 0.01% sodium azide solution in PBS, incubated for 24 hr and imaged in this medium. Imaging was performed on a Leica TCS SP8 STED 3X using HC FLUOTAR L VISIR 25x water lenses.
Electron microscopy of LN conduits
LNs were fixed overnight in 2% PFA/1.5% glutaraldehyde (both EM grade from TAAB) in 0.1M sodium Cacodylate at 4 C and embedded in 2.8% low melting point agarose dissolved in PBS. Slices of 100 mm thickness were then cut in cold PBS using a vibrating microtome (VT1200S; Leica) and returned to fresh fix solution for a further 15 mins. Slices were then secondarily fixed for 1 h in 1% osmium tetraoxide/1.5% potassium ferricyanide at 4 C and then treated with 1% tannic acid in 0.1M sodium cacodylate for 45min at room temperature. Samples were then dehydrated in sequentially increasing concentration of ethanol solutions, and embedded in Epon resin. The 70nm ultrathin resin sections were cut with a Diatome 45 diamond knife using an ultramicrotome Bgn S100a4
Ctsl Lgals1 Figure S5 . Gating strategy and population analysis for in vivo antigen uptake. A) Representative dot plots showing gating strategy. Live cells were gated according to FSC/SSC parameters and doublets were excluded prior to analysis. Total cells were used to gate dendritic cell ( 
